Sentences with phrase «immunotherapy ipilimumab»

Dr. Fong is experienced in research and clinical studies with the dendritic cell immunotherapy vaccine sipuleucel - T (Provenge) as well as the anti-CTLA-4 checkpoint immunotherapy ipilimumab.

Not exact matches

BMS's drug, ipilimumab (Yervoy), was the first checkpoint inhibitor (a kind of cancer immunotherapy drug that essentially helps the immune system release its brake and go after tumor cells it might normally miss) to get approved in the US in 2011 for melanoma.

The next year, the FDA approved another immunotherapy agent, ipilimumab, to treat melanoma.

They studied the effects of this treatment in combination with ipilimumab, a U.S. Food and Drug Administration - approved immunotherapy.

Ipilimumab, sold as Yervoy, is an immunotherapy drug consisting of a monoclonal antibody that targets a protein receptor, CTLA - 4.

To investigate why checkpoint inhibitors so often stop working, Velculescu; Valsamo Anagnostou, M.D., Ph.D., instructor of oncology at the Johns Hopkins University School of Medicine; Kellie N. Smith, Ph.D., a cancer immunology research associate at the Johns Hopkins University School of Medicine; and their colleagues at the Bloomberg ~ Kimmel Institute for Cancer Immunotherapy studied tumors of four patients with non-small cell lung cancer and one patient with head and neck cancer who developed resistance to two different checkpoint inhibitors: a drug called nivolumab that uses an antibody called anti-PD-1, or nivolumab used alone or in combination with a second drug called ipilimumab, which uses an antibody called anti-CTLA4.

Combination immunotherapy with nivolumab and ipilimumab as tested in the kidney cancer study described here is already FDA - approved for treatment of melanoma, and is being tested for other cancers.

The U.S. Food and Drug Administration granted approval to the combination of two immunotherapy drugs, ipilimumab and nivolumab, for the treatment of metastatic kidney cancer.

With enthusiasm for cancer immunotherapy mounting thanks to recent successes in the clinic with immune - based cancer treatments such as anti-CTLA-4 and anti-PD-1 antibodies, and the FDA approvals of sipuleucel - T prostate cancer vaccine and ipilimumab for the treatment of melanoma, and in light of the many promising immunotherapies now in clinical trials with potential for near - term FDA approval, the Cancer Research Institute launched the first annual Cancer Immunotherapy Awareness Month in June 2013 as a way to increase public awareness of the power of immunotherapy to revolutionize cancer treatment and of the need for continued public support for research to bring these treatments to more patimmunotherapy mounting thanks to recent successes in the clinic with immune - based cancer treatments such as anti-CTLA-4 and anti-PD-1 antibodies, and the FDA approvals of sipuleucel - T prostate cancer vaccine and ipilimumab for the treatment of melanoma, and in light of the many promising immunotherapies now in clinical trials with potential for near - term FDA approval, the Cancer Research Institute launched the first annual Cancer Immunotherapy Awareness Month in June 2013 as a way to increase public awareness of the power of immunotherapy to revolutionize cancer treatment and of the need for continued public support for research to bring these treatments to more patImmunotherapy Awareness Month in June 2013 as a way to increase public awareness of the power of immunotherapy to revolutionize cancer treatment and of the need for continued public support for research to bring these treatments to more patimmunotherapy to revolutionize cancer treatment and of the need for continued public support for research to bring these treatments to more patients sooner.

The other major class of immunotherapies are known as anti-CTLA-4 treatments, such as ipilimumab (Yervoy), which target a different mechanism to unleash immune cells to fight tumors.

Current clinical trials include combination of intrahepatic embolization and a radiosensitizer in patients with uveal melanoma and liver - only metastases, a phase I trial that evaluates a combination therapy of BCG with ipilimumab in Stage III / IV melanoma, and several landmark international trials including a phase II trial that evaluates combination immunotherapy with nivolumab & ipilimumab.

Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology.

Dr. Wolchok has been at the forefront of cancer immunotherapy and is renowned for leading the clinical trials that led to the first FDA - approved checkpoint inhibitor immunotherapy, the anti-CTLA-4 antibody ipilimumab.

The immunotherapy drugs are ipilimumab (Yervoy ®), pembrolizumab (Keytruda ®), nivolumab (Opdivo ®), and talimogene laherparepvec (T - VEC, Imlygic ™).

«Ipilimumab provides a way to overcome one of the most potent barriers to successful cancer immunotherapy — the ability of cancer to selectively suppress the response of immune cells to the cancer and shut down immune attack,» says Lloyd J. Old, M.D., director of the CRI Scientific Advisory Council.

This may be best addressed by a tailored development paradigm,» says CIC Executive Committee member and a lead investigator in the ipilimumab clinical development program Jedd D. Wolchok, M.D., Ph.D., who is director of the Immunotherapy Clinical Trials Program at Memorial Sloan - Kettering Cancer Center in New York City.

Ipilimumab is the second active immunotherapy for cancer to be approved by the FDA, following the approval in April 2010 of sipuleucel - T (Provenge ®) for advanced castrate - resistant prostate cancer.

The positive results from the two phase III studies of ipilimumab were made possible in part through the evolution of the clinical science, which is based on new models of academic - industry partnership to advance immunotherapy development.

In one series reported in 2014, when checkpoint therapy largely consisted of ipilimumab, «there were some challenges giving up front BRAF - inhibitor therapy and then trying to treat with immunotherapy,» said Salama.

Phase 1b study of a novel immunotherapy combination therapy of intralesional Coxsackievirus A21 and systemic ipilimumab in patients with advanced melanoma.

In the spring of 2011, the FDA approved the immunotherapy treatment ipilimumab, known by the brand name Yervoy.